pJEK1 Alpha-Synuclein Vector
Invented by Dr Fiona Benson from Lancaster University
Invented at Lancaster University
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 152046 |
| Antigen/Gene or Protein Targets | Alpha-synuclein |
| Relevance | Alpha-synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. |
| Research Area | Neurobiology |
| Notes |
pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag. 2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section. |
References: 2 entries
El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
Europe PMC ID: 15180968
Add a reference
References: 2 entries
El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
Add a reference
